

### **ZEPOSIA (ozanimod) PRIOR AUTHORIZATION FORM**

*(form effective 1/3/2022)*

Prior authorization guidelines for **Zeposia** and **Quantity Limits/Daily Dose Limits** are available on Geisinger Health Plan's website at <https://healthplan.geisinger.org/pharmacy/pharmacy.aspx?strip=true&style=OneGeisinger>

<input type="checkbox"/> New request	<input type="checkbox"/> Renewal request	total pages: _____	Prescriber name:	
Name of office contact:			Specialty:	
Contact's phone number:			NPI:	MA Provider ID#:
LTC facility contact/phone:			Street address:	
Beneficiary Name:			Suite #:	City/state/zip:
Beneficiary ID#:	DOB:	Phone:	Fax:	

### **CLINICAL INFORMATION**

Drug requested <i>(check all products being requested):</i>	<input type="checkbox"/> Zeposia 7-Day Starter Pack [(4) 0.23 mg capsules and (3) 0.46 mg capsules] --- Quantity: 1 pack for 7 days <input type="checkbox"/> Zeposia Starter Kit [(4) 0.23 mg capsules, (3) 0.46 mg capsules, and (30) 0.92 mg capsules] --- Quantity: 1 pack for 37 days <input type="checkbox"/> Zeposia capsule Strength: _____ mg Quantity: _____ Refills: _____ <input type="checkbox"/> Zeposia _____ Quantity: _____ Refills: _____			
Directions:	<input type="checkbox"/> 0.23 mg QD days 1 through 4, then 0.46 mg QD days 5 through 7, then 0.92 mg QD thereafter <input type="checkbox"/> 0.92 mg QD <input type="checkbox"/> other: _____			
Diagnosis <i>(submit documentation)</i> :			Dx code <i>(required)</i> :	
Is the beneficiary currently being treated with Zeposia?			<input type="checkbox"/> Yes <i>Submit documentation.</i> <input type="checkbox"/> No	
Is Zeposia being prescribed by or in consultation with a neurologist or gastroenterologist?			<input type="checkbox"/> Yes <i>Submit documentation of consultation if applicable.</i> <input type="checkbox"/> No	

**Check all of the following that apply to the beneficiary and SUBMIT DOCUMENTATION for each item.**

- Has severe untreated sleep apnea
- Will be taking a monoamine oxidase inhibitor while taking Zeposia (e.g., selegiline, phenelzine)
- Has a comorbid heart condition – describe: \_\_\_\_\_
- Experienced any of the following in the past 6 months:
 

<input type="checkbox"/> Myocardial infarction	<input type="checkbox"/> Transient ischemic attack
<input type="checkbox"/> Unstable angina	<input type="checkbox"/> Decompensated heart failure
<input type="checkbox"/> Stroke	<input type="checkbox"/> Class III/IV heart failure

### **INITIAL requests**

**Check all of the following that apply to the beneficiary and this request and SUBMIT DOCUMENTATION for each item.**

- Is being treated for MULTIPLE SCLEROSIS (MS):**
  - Has a relapsing form of MS

- Tried and failed or has a contraindication or an intolerance to the preferred Multiple Sclerosis Agents that are FDA-approved or medically accepted for the treatment of MS. Refer to <https://papdl.com/preferred-drug-list> for a list of preferred Multiple Sclerosis Agents.
- Is being treated for ULCERATIVE COLITIS (UC):**
- Has moderate-to-severe disease
  - Has disease that is associated with high-risk or poor prognostic features
  - Failed to achieve remission with an induction course of corticosteroids
  - Has a contraindication or intolerance to an induction course of corticosteroids
  - Failed to maintain remission with an immunomodulator (e.g., AZA, cyclosporine, 6-MP, MTX)
  - Has a contraindication or intolerance to immunomodulators (e.g., AZA, cyclosporine, 6-MP, MTX)
  - Tried and failed or has a contraindication or intolerance to the preferred Cytokine and CAM Antagonists that are FDA-approved or medically accepted for the treatment of UC. Refer to <https://papdl.com/preferred-drug-list> for a list of preferred Cytokine and CAM Antagonists.

**RENEWAL requests**

**Check all of the following that apply to the beneficiary and this request and SUBMIT DOCUMENTATION for each item.**

- For a diagnosis of MULTIPLE SCLEROSIS, experienced improvement or stabilization of the MS disease course since starting Zeposia
- For a diagnosis of ULCERATIVE COLITIS, experienced improvement in disease activity or level of functioning since starting Zeposia

**Please submit to PromptPA <https://ghp.promptpa.com> OR fax to Geisinger Health Plan at 570-271-5610 the completed form with required clinical documentation.**

**Prescriber Signature:**

**Date:**

**Confidentiality Notice:** The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.